IP Library Granted Patent US 11,371,062
Granted Patent B2
US 11,371,062 · App. 16/335,630 · Granted Jun 28, 2022

RNA-guided nucleic acid modifying enzymes and methods of use thereof

Inventors: Jennifer A. Doudna (Berkeley, CA); Jillian F. Banfield (Berkeley, CA); David Burstein (Berkeley, CA); Lucas Benjamin Harrington (Berkeley, CA)
Assignee: The Regents of the University of California
C12N15/902A61K38/46C12N9/22C12N15/113C12N2310/20C12N2740/16043C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,371,062
App. No.
16/335,630
Granted
Jun 28, 2022
Kind
B2
Abstract

The present disclosure provides CasY proteins, nucleic acids encoding the CasY proteins, and modified host cells comprising the CasY proteins and/or nucleic acids encoding same. CasY proteins are useful in a variety of applications, which are provided. The present disclosure provides CasY guide RNAs that bind to and provide sequence specificity to the CasY proteins, nucleic acids encoding the CasY guide RNAs, and modified host cells comprising the CasY guide RNAs and/or nucleic acids encoding same. CasY guide RNAs are useful in a variety of applications, which are provided. The present disclosure provides methods of identifying a CRISPR RNA-guided endonuclease.

Claims (42)

1. A composition comprising:

a) a CasY fusion polypeptide, or a nucleic acid molecule encoding the CasY fusion polypeptide, wherein the CasY fusion polypeptide comprises a CasY polypeptide fused to a heterologous polypeptide, and wherein the CasY polypeptide comprises an amino acid sequence having 50% or more identity to the amino acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:2; and

b) a CasY guide RNA, or one or more DNA molecules encoding the CasY guide RNA.

2. The composition of claim 1 , wherein the CasY polypeptide comprises an amino acid sequence having 80% or more identity to the amino acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:2.

3. The composition of claim 1 , wherein the heterologous polypeptide is a nuclear localization signal.

4. The composition of claim 1 , comprising one or more of: a buffer, a nuclease inhibitor, a lipid, and a protease inhibitor.

5. The composition of claim 1 , wherein the CasY polypeptide is a catalytically inactive CasY Polypeptide (dCasY).

6. The composition of claim 5 , wherein the CasY polypeptide comprises one or more mutations at a position corresponding to those selected from: D828, E914, and D1074 of SEQ ID NO: 1.

7. The composition of claim 1 , further comprising a DNA donor template.

8. A CasY fusion polypeptide comprising: a CasY polypeptide fused to a heterologous polypeptide, wherein the CasY polypeptide comprises an amino acid sequence having 50% or more identity to the amino acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:2.

9. The CasY fusion polypeptide of claim 8 , wherein the CasY polypeptide comprises an amino acid sequence having 59% 80% or more identity to the amino acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:2.

10. The CasY fusion polypeptide of claim 8 , wherein the CasY polypeptide is a catalytically inactive CasY Polypeptide (dCasY).

11. The CasY fusion polypeptide of claim 10 , wherein the CasY polypeptide comprises one or more mutations at a position corresponding to those selected from: D828, E914, and D1074 of SEQ ID NO: 1.

12. The CasY fusion polypeptide of claim 8 , wherein the heterologous polypeptide is a targeting polypeptide that provides for binding to a cell surface moiety on a target cell or target cell type.

13. The CasY fusion polypeptide of claim 8 , wherein the heterologous polypeptide exhibits an enzymatic activity that modifies target DNA.

14. The CasY fusion polypeptide of claim 8 , wherein the heterologous polypeptide exhibits an enzymatic activity that modifies a target polypeptide associated with a target nucleic acid.

15. The CasY fusion polypeptide of claim 8 , wherein the heterologous polypeptide is an endosomal escape polypeptide.

16. The CasY fusion polypeptide of claim 8 , wherein the heterologous polypeptide is a protein that increases or decreases transcription.

17. A nucleic acid comprising a nucleotide sequence encoding a CasY fusion polypeptide, wherein the CasY fusion polypeptide comprises a CasY polypeptide fused to a heterologous polypeptide, wherein the CasY polypeptide comprises an amino acid sequence having 50% or more identity to the amino acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:2.

18. One or more nucleic acid molecules encoding:

(a) a CasY guide RNA; and

(b) a CasY fusion polypeptide, wherein the CasY fusion polypeptide comprises a CasY polypeptide fused to a heterologous polypeptide, and wherein the CasY polypeptide comprises an amino acid sequence having 50% or more identity to the amino acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:2.

19. The one or more nucleic acid molecules of claim 18 , wherein the CasY polypeptide comprises an amino acid sequence having 80% or more identity to the amino acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:2.

20. A eukaryotic cell comprising one or more of:

a) a CasY polypeptide, or a nucleic acid molecule encoding the CasY polypeptide, wherein the CasY polypeptide comprises an amino acid sequence having 50% or more identity to the amino acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:2;

b) a CasY fusion polypeptide, or a nucleic acid molecule encoding the CasY fusion polypeptide, wherein the CasY fusion polypeptide comprises a CasY polypeptide fused to a heterologous polypeptide, and wherein the CasY polypeptide comprises an amino acid sequence having 50% or more identity to the amino acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:2; and

c) a CasY guide RNA, or a nucleic acid molecule encoding the CasY guide RNA.

21. A cell comprising a CasY fusion polypeptide, or a nucleic acid molecule encoding the CasY fusion polypeptide, wherein the CasY fusion polypeptide comprises a CasY polypeptide fused to a heterologous polypeptide, and wherein the CasY polypeptide comprises an amino acid sequence having 50% or more identity to the amino acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:2.

22. A method of modifying a target nucleic acid, the method comprising contacting the target nucleic acid with:

a) a CasY polypeptide, wherein the CasY polypeptide comprises an amino acid sequence having 50% or more identity to the amino acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:2; and

b) a CasY guide RNA comprising a guide sequence that hybridizes to a target sequence of the target nucleic acid,

wherein the target nucleic acid is double-stranded DNA, and

wherein said contacting results in modification of the target nucleic acid by the CasY polypeptide.

23. The method of claim 22 , wherein said modification is cleavage of the target nucleic acid.

24. The method of claim 22 , wherein the target nucleic acid is genomic DNA or extrachromosomal DNA.

25. The method of claim 22 , wherein said contacting takes place in vitro outside of a cell.

26. The method of claim 22 , wherein said contacting takes place inside of a cell in vivo.

27. The method of claim 26 , wherein the cell is a eukaryotic cell.

28. A method of modulating transcription from a target DNA, modifying a target nucleic acid, or modifying a protein associated with a target nucleic acid, the method comprising contacting the target nucleic acid with:

a) a CasY fusion polypeptide comprising a CasY polypeptide fused to a heterologous polypeptide, wherein the CasY polypeptide comprises an amino acid sequence having 50% or more identity to the amino acid sequence set forth in SEO ID NO: 1 or SEO ID NO:2; and

b) a CasY guide RNA comprising a guide sequence that hybridizes to a target sequence of the target nucleic acid,

wherein the target nucleic acid is double-stranded DNA.

Assignments (6)
CORRECTION BY DECLARATION TO CORRECT CONVEYANCE AND DOCUMENTS ERRONEOUSLY FILED AT 055223/0805 Recorded Sep 19, 2023
From: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 064953/0528 →
CORRECTION BY DECLARATION TO CORRECT CONVEYANCE AND DOCUMENTS ERRONEOUSLY FILED AT 057525/0141 Recorded Sep 19, 2023
From: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 064953/0687 →
CORRECTIVE BY NULLIFICATION TO CORRECT INCORRECTLY RECORDED APPLICATION/PATENT NUMBERS (SEE ATTACHMENT) AT REEL/FRAME 055223/0805. ASSIGNOR HEREBY CONFIRMS THE CHANGE OF ADDRESS. Recorded Sep 16, 2021
From: MAMMOTH BIOSCIENCES, INC.
To: MAMMOTH BIOSCIENCES, INC.
Reel/Frame 057525/0141 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2021
From: DOUDNA, JENNIFER A.; BANFIELD, JILLIAN F.; BURSTEIN, DAVID; HARRINGTON, LUCAS BENJAMIN
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 055936/0391 →
CHANGE OF ADDRESS OF THE ASSIGNEE Recorded Feb 4, 2021
From: MAMMOTH BIOSCIENCES, INC.
To: MAMMOTH BIOSCIENCES, INC.
Reel/Frame 055223/0805 →
CONFIRMATORY LICENSE Recorded Jul 15, 2020
From: UNIVERSITY OF CALIFORNIA, BERKELEY
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 053222/0920 →
Cited By (1)
US 12,637,691